These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22169256)

  • 1. Toxic epidermal necrolysis: review of pathogenesis and management.
    Downey A; Jackson C; Harun N; Cooper A
    J Am Acad Dermatol; 2012 Jun; 66(6):995-1003. PubMed ID: 22169256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin.
    Romanelli P; Schlam E; Green JB; Trent JT; Ricotti C; Elgart GW; Kirsner RS; Kerdel FA
    G Ital Dermatol Venereol; 2008 Aug; 143(4):229-33. PubMed ID: 18833079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic epidermal necrolysis.
    Pereira FA; Mudgil AV; Rosmarin DM
    J Am Acad Dermatol; 2007 Feb; 56(2):181-200. PubMed ID: 17224365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].
    Molgó M; Carreño N; Hoyos-Bachiloglu R; Andresen M; González S
    Rev Med Chil; 2009 Mar; 137(3):383-9. PubMed ID: 19621180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report.
    Lissia M; Figus A; Rubino C
    Br J Plast Surg; 2005 Jun; 58(4):504-10. PubMed ID: 15897036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Koh MJ; Tay YK
    Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
    French LE; Trent JT; Kerdel FA
    Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic epidermal necrolysis: current evidence, practical management and future directions.
    Chave TA; Mortimer NJ; Sladden MJ; Hall AP; Hutchinson PE
    Br J Dermatol; 2005 Aug; 153(2):241-53. PubMed ID: 16086734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic epidermal necrolysis (Lyell's disease).
    Lissia M; Mulas P; Bulla A; Rubino C
    Burns; 2010 Mar; 36(2):152-63. PubMed ID: 19766401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis.
    Szczeklik W; Nowak I; Seczynska B; Sega A; Krolikowski W; Musial J
    Ther Apher Dial; 2010 Jun; 14(3):354-7. PubMed ID: 20609191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of toxic epidermal necrolysis.
    Fernando SL
    Australas J Dermatol; 2012 Aug; 53(3):165-71. PubMed ID: 22881464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In a patient with toxic epidermal necrolysis, does intravenous immunoglobulin improve survival compared with supportive care?
    Wootton CI; Patel AN; Williams HC
    Arch Dermatol; 2011 Dec; 147(12):1437-40. PubMed ID: 22184767
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxic epidermal necrolysis 2006.
    Heymann WR
    J Am Acad Dermatol; 2006 Nov; 55(5):867-9. PubMed ID: 17052494
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxic epidermal necrolysis and intravenous immunoglobulin: a review.
    Trent J; Halem M; French LE; Kerdel F
    Semin Cutan Med Surg; 2006 Jun; 25(2):91-3. PubMed ID: 16908399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe cutaneous adverse reactions to drugs.
    Chia FL; Leong KP
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fromowitz JS; Ramos-Caro FA; Flowers FP;
    Int J Dermatol; 2007 Oct; 46(10):1092-4. PubMed ID: 17910723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis.
    Paquet P; Jacob E; Damas P; Pirson J; Piérard G
    Arch Dermatol Res; 2005 Dec; 297(6):266-73. PubMed ID: 16249890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases.
    Koštál M; Bláha M; Lánská M; Koštálová M; Bláha V; Štepánová E; Malý J
    J Clin Apher; 2012; 27(4):215-20. PubMed ID: 22407895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin.
    Gaitanis G; Spyridonos P; Patmanidis K; Koulouras V; Nakos G; Tzaphlidou M; Bassukas ID
    Dermatology; 2012; 224(2):134-9. PubMed ID: 22572593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.